Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
operation-income-chart

PFE Operation Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) Operation Income in Q4'25 shows a loss of $1.64B USD, marking a significant downturn from the positive figures in the preceding quarters of 2025. This represents a sharp decline compared to the $3.33B USD profit in Q3'25, contributing to a year-over-year change of -163.4%. Over the period from Q1'23 to Q4'25, Operation Income exhibits high volatility with alternating profits and losses, starting with a strong $6.27B USD in Q1'23 before plunging into negative territory in Q3'23 (-$3.35B USD) and Q4'23 (-$4.13B USD), the lowest points. Recovery occurred in Q1'24 ($3.42B USD) and Q3'24 ($4.72B USD), but instability persisted with minor losses in Q2'24 and Q4'24, followed by consistent profits in Q1'25 to Q3'25 (ranging from $2.79B USD to $3.34B USD) before the Q4'25 reversal. Year-over-year growth was predominantly negative until Q3'24 (240.7%) and Q2'25 (3,026.9%), highlighting erratic performance likely influenced by operational or market factors.